Torrent Pharmaceuticals Ltd. NSE: TORNTPHARM | BSE: 500420

Expensive Performer

Download real time

3585.00 -18.20 (-0.51%)

213.4K

NSE+BSE Volume

NSE 01 Oct, 2025 1:49 PM (IST)

Torrent Pharmaceuticals Ltd. share price target

Torrent Pharmaceuticals Ltd. has an average share price target of 3746. The consensus estimate represents an upside of 4.49% from the last price of 3585. View 11 reports from 5 analysts offering long-term price targets for Torrent Pharmaceuticals Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	01 Oct 2025	Torrent Pharma	Consensus Share Price Target	3585.00	3929.42	-	9.61	buy	pdf Detailed Estimates
	01 Aug 2022	Torrent Pharma	Prabhudas Lilladhar	3585.00	1750.00	1517.25 (136.28%)	Target met	Buy	pdf post cache		Broker Report TORRENT PHARMACEUTIC Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	30 Jul 2022	Torrent Pharma	Motilal Oswal	3585.00	1510.00	1525.65 (134.98%)	Target met	Neutral	pdf post cache		Broker Report Promising outlook for India and Brazil segments Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	30 Jul 2022	Torrent Pharma	ICICI Direct	3585.00	1800.00	1528.80 (134.50%)	Target met	Buy	pdf post cache		Broker Report Torrent Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	08 Jul 2022	Torrent Pharma	ICICI Direct	3585.00	1615.00	1466.70 (144.43%)	Pre-Bonus/ Split	Hold	pdf post cache		Broker Report Torrent Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	26 May 2022	Torrent Pharma	ICICI Direct	3585.00	3235.00	2900.95 (23.58%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report V-Mart Ltd. ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	26 May 2022	Torrent Pharma	ICICI Direct	3585.00	3235.00	2900.95 (23.58%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report Torrent Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	26 May 2022	Torrent Pharma	Motilal Oswal Target	3585.00	2850.00	2900.95 (23.58%)	Target met	Neutral	pdf post cache		Broker Report India/Brazil outshine; decline in the US sales growth ceases Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	26 May 2022	Torrent Pharma	Prabhudas Lilladhar Target	3585.00	3250.00	2936.95 (22.07%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report TORRENT PHARMACEUTIC Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	07 Feb 2022	Torrent Pharma	Geojit BNP Paribas Target	3585.00	3095.00	2590.60 (38.38%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report TORRENT PHARMA Geojit BNP Paribas Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. The company... pdf Copy Link Share on Share on Share on Share on Alert
	27 Jan 2022	Torrent Pharma	Prabhudas Lilladhar	3585.00	3560.00	2657.65 (34.89%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report TORRENT PHARMACEUTIC Prabhudas Lilladhar Torrent Pharma's (TRP) Q3FY22 performance was disappointing however we believe profitability/margins to normalize from FY23, aided by price hike in branded generic business and current cost escalation temporary. TRP's high exposure to branded generic business (~65-70% of total revenues) and chronic therapies provides comfort. The timely resolution of plants will pickup revenue growth in US and benefit operating leverage, going ahead. We expect 18% EPS CAGR over FY21-24E. We have cut our FY22E EPS by 6%... pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners